EE162 Healthcare Resource Utilization and 2022 Cost Update of Cytokine Release Syndrome and Neurotoxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Idecabtagene Vicleucel (IDE-CEL, BB2121) in KarMMa
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.464
https://www.valueinhealthjournal.com/article/S1098-3015(23)00564-8/fulltext
Title :
EE162 Healthcare Resource Utilization and 2022 Cost Update of Cytokine Release Syndrome and Neurotoxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Idecabtagene Vicleucel (IDE-CEL, BB2121) in KarMMa
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00564-8&doi=10.1016/j.jval.2023.03.464
First page :
Section Title :
Open access? :
No
Section Order :
11845